All News

#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ

#ACR 2024 BEST Abstracts from Day 1 | RheumNow

Would you trust #AI to carry out & read your #USS? 2 systems, ARTHUR & DIANA, were comparable to that of a rheumatologist specialising in MSK US at joint & patient levels Might this be the future of assessment in rheumatology care? AbL20 #ACR24 @RheumNow https://t.co/XtnlYafzp4

https://x.com/DrMiniDey/status/1858883428370051118/photo/1

Nailfold video capillaroscopy (NVC) allows the definite distinction between primary and secondary #Raynaud's phenomenon and can identify early changes such as few giant capillaries &/or microhemorrages promoting early diagnosis @RheumNow #ACR24 @rheumarhyme https://t.co/Yl37w6BEZR

https://x.com/RHEUMarampa/status/1858886053236506940/photo/1

Another + #SLE #RCT - large N #Dapirolizumab = Peg CD40L + SoC Vs #Placebo + SoC Rapid improvemt steroid sparing So what to use in Pts if +Ph3 👇 TYK2 Deucravacitinib JAKi Upadacitinib Dapirolizumab CAR 🚗 Rx Anifrolimumab Benlysta ETC! #ACRBest L16 @RheumNow #ACR24 https://t.co/wTFucF7BYO

https://twitter.com/sgrheumer/status/1858869670012489927

Late breaking abstract L17 CAR-NK Therapy for Refractory SLE. In a trial of 20 severe SLE patients: - 75% achieved LLDAS, 50% achieved DORIS remission at 6 months - B cell reconstitution: 2–3 months post-treatment - Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o

https://x.com/i/web/status/1858887962349760575

The combe-like pattern is observed in pts with APS and also in overlap syndrome - presence of parallel microthrombi (orange arrow) arranged perpendicularly, hence combe-like @RheumNow #ACR24 @rheumarhyme https://t.co/IjX7ld9lxW

https://x.com/RHEUMarampa/status/1858889996213665793/photo/1

The #scleroderma-like pattern on NVC is observed in pts with #dermatomyositis and MCTD It consists of a combination of giant capillaries, some microhemorrhages, severe capillary loss and angiogenesis @RheumNow #ACR24 @rheumarhyme https://t.co/WO9BOYn4ir

https://x.com/RHEUMarampa/status/1858889980426199304/photo/1

In Vivo CAR T Cell Therapy. A single intralymphatic injection of VivoVec™ particles: - Generates functional CAR T cells in vivo - Achieves complete B cell depletion in NHPs without lymphodepletion - Demonstrates potential for an off-the-shelf solution for autoimmune disease… https://t.co/5DTzRvZjbY https://t.co/DvTOqnhn1V

Are weight loss drugs in #high #BMI In #Rheumatoid #arthritis A #DMARD? Yr in preview #ACR24 @RheumNow @ACRheum https://t.co/Hd1y0fFYxY

Wt ⬇️ = Better #PROs in 👇autoimmune #rheumatic #diseases if > 5% wt loss. #ACR24 ⁦@ACRheum⁩ ⁦@RheumNow⁩ Didn’t work for non overwt Ex Normal BMI and T2DM 🤷 https://t.co/81OuTfZ0Nx

https://x.com/Janetbirdope/status/1858892960063963347/photo/1

🚨 New SLE treatment update! 🚨 Dapirolizumab pegol (DZP), novel CD40L inhibitor, for moderate-to-severe lupus. Phase 3 trial, DZP reduced disease activity, helped taper steroids, and achieved a higher BICLA Safe and generally well tolerated! #ACR24 #L16 @rheumnow https://t.co/lFrKjz4CZ1

https://x.com/bella_mehta/status/1858893243057897860/photo/1

In this study by Dr CArriens et al, there was no difference between the vaccine response to Influenza by either HAI or Ab levels in Anifrolumab-treated pts. AEs - mild, moderate No serious aEs 💉#vaccinate your pts on anifrolumab with influenza @RheumNow #ACR24 abs2424 https://t.co/XPwlzUS02i

Mitochondria: the powerhouse of the cell—but the fuel behind gout flares? #ACR24 @RheumNow https://t.co/lV4dovLV18

https://twitter.com/tuhina_neogi/status/1858614167109816655

#CRISPR reviewed in 👇 #fibroblasts Found deletion of certain genes Ex JIA had marked change in expression Yr in Preview ACR24 @RheumNow @ACRheum Dr Chris Ritchlin 👏 https://t.co/jnmtk1eXGp

https://x.com/Janetbirdope/status/1858895113872707672/photo/1

Mortality Risk After Stopping Glucocorticosteroids (GC) in RA. In a study of 28,078 RA patients: Mortality risk from CVD ↑ 7.5%/year of GC use; ↓ 1.3%/year after stopping. Mortality risk from infections ↑ 6.8%/year of GC use; ↓ 4.9%/year after stopping. Risks normalize 1.5–10… https://t.co/i6cKet1EEV https://t.co/ClMjIly20E

Did you know? 🤔 Capillaroscopy is performed on the nailfold because it is the area where the capillaries are fully visualized compared to the skin where capillary tips are only seen. This capillaroscopy session with Dr. Cutolo is so high yield I'd say! 🤓 @RheumNow #ACR24 https://t.co/8AN7RXUDrM

https://x.com/RHEUMarampa/status/1858897030413762965/photo/1

#Poorer responses to #Rx in #Females vs #males Sex hormone and pathway differences explained 👇 Biological differences F start worse in disease activity F May have ⬇️ response to #Rx Yr in Preview C Ritchlin @lihi_eder’s PsA work quoted ACR24 @RheumNow @ACRheum @ACRBest https://t.co/EWoCvzOLiL

https://x.com/Janetbirdope/status/1858898119162843619/photo/1

VACIMRA Study showed timing matters for Methotrexate and Pneumococcal Vaccine in RA. RA patients vaccinated with PCV13 1 month before MTX initiation had higher responder rates at 1 month: 88% (ELISA) vs. 75% 96% (OPA) vs. 88% At 12 months, responses remained stronger in… https://t.co/bSbIazsRtG

https://x.com/i/web/status/1858899283182821530

Hydralazine - known culprit of drug-induced AAV How does hydral (H) AAV differ from primary (1) AAV? 💥 High dual positivity MPO/PR3 💥 DAH / pleuritis more common in H-AAV 💥 ENT, constitutional, nervous, ILD in 1-AAV 💥 More 6mo remission in H-AAV @rheumnow #ACR24 Abst 2496

Weinblatt et al. AMPLIFIED trial. No difference in response rates of RA to adalimumab or abatacept based on dual seropositivity/shared epitope status. Fits with my priors and refutes a previous pilot study. @RheumNow #ACR24 Abstr#2671 https://t.co/OUwnlsP6jU https://t.co/RBN6ivSKDr

Topics

All News

Do you get our email newsletter?